InvestLog
FBRX Forte Biosciences, Inc. logo

FBRX Forte Biosciences, Inc.

Healthcare
$21.59-1.86%ClosedMarket Cap: $299.8M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

91.47

P/S

0.00

EV/EBITDA

-3.17

DCF Value

$0.47

FCF Yield

-19.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-106.2%

ROA

-112.8%

ROIC

-176.6%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-22.1M$—
Q4 null$0.00$-24.8M$—
FY null$0.00$-69.4M$—
Q3 null$0.00$-17.7M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$65.00

Target (Median)

$65.00

Target Range

$65.00 - $65.00

0 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell
Chardan CapitalBuy
2025-11-17
Chardan CapitalBuy
2025-08-15
Chardan CapitalBuy
2025-06-24

Trading Activity

Insider Trades

View All
Wagner Paul A.director, officer: SEE REMARKS
SellFri Apr 03
Wagner Paul A.director, officer: SEE REMARKS
SellFri Apr 03
Riley Antony Aofficer: CHIEF FINANCIAL OFFICER
SellFri Apr 03
Riley Antony Aofficer: CHIEF FINANCIAL OFFICER
SellFri Apr 03
Wagner Paul A.director, officer: SEE REMARKS
SellTue Jan 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

—

Beta

3.00

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.

Peers

ACTU logoACTUALEC logoALECAPLT logoAPLTCRBP logoCRBPCRDF logoCRDFELTX logoELTXFATE logoFATEMOLN logoMOLNNKTX logoNKTXPEPG logoPEPG